Effect of long‐term treatment with a small‐molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function
暂无分享,去创建一个
[1] Y. Terauchi,et al. Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass. , 2009, Endocrinology.
[2] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[3] H. Aburatani,et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. , 2007, The Journal of clinical investigation.
[4] A. Kadotani,et al. An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism* , 2006, Journal of Biological Chemistry.
[5] Yun-ping Zhou,et al. A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. , 2010, European journal of pharmacology.
[6] J. Grippo,et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. , 2001, Diabetes.
[7] N. Hashimoto,et al. Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. , 2009, Bioorganic & medicinal chemistry.
[8] M. Magnuson,et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. , 2006, Diabetes.
[9] J. Grippo,et al. Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.
[10] J. Agudo,et al. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance , 2003, Diabetologia.
[11] F. Matschinsky,et al. Assessing the potential of glucokinase activators in diabetes therapy , 2009, Nature Reviews Drug Discovery.